Curated News
By: NewsRamp Editorial Staff
October 08, 2026
Helus Pharma to Host Investor Webinar on Psychedelic-Inspired Depression and Anxiety Treatments
TLDR
- Helus Pharma's Phase 3 HLP003 holds Breakthrough Therapy Designation, offering a competitive edge in the depression treatment market.
- Helus Pharma will host an investor presentation on Oct. 21, 2026, detailing HLP003 and HLP004 clinical progress and mechanisms.
- Helus Pharma's novel serotonergic agonists aim to heal minds by providing durable improvements for depression and anxiety sufferers.
- Helus Pharma's synthetic molecules target serotonin pathways to promote neuroplasticity, potentially revolutionizing mental health treatment.
Impact - Why it Matters
This news matters because it highlights a critical juncture in mental health treatment. Major depressive disorder and generalized anxiety disorder affect millions worldwide, and current therapies often fail to provide durable relief. Helus Pharma's NSAs represent a novel approach that could transform the standard of care. With HLP003 in Phase 3 and Breakthrough Therapy Designation, and HLP004 in Phase 2, the company is advancing a pipeline that, if successful, could offer new hope for patients who have not responded to existing treatments. The investor presentation provides a window into this progress, signaling potential for significant clinical and commercial impact. As the mental health crisis escalates, innovations like these are essential, and stakeholders—from patients to investors—should pay close attention.
Summary
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), will host an investor presentation on October 21, 2026, at 9 a.m. EDT. The event will spotlight two lead candidates: HLP003, a proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder (MDD) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, a proprietary NSA in Phase 2 development for generalized anxiety disorder (GAD). The presentation will also include perspectives from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a Q&A session with Helus Pharma executives. The live webcast will be accessible through the company’s website, with a replay available afterward.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on social media. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
The announcement is disseminated through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma to Host Investor Webinar on Psychedelic-Inspired Depression and Anxiety Treatments
